vad regimen as initial treatment for multiple myeloma
نویسندگان
چکیده
introduction: the aim of our study is evaluation of response rate of vad (vincristin, adriamycin and dexamethason) regimen as initial treatment in 40 new cases of multiple myeloma. this is the first systemic and classic report of vad regimen in iranian population. methods: all patients with at least stage 2 multiple myeloma or progressive disease after physical examination, para- clinical profile such as (imaging, cbc, bun, creatinine, ca, p, alk phos, protein eletrophoresis, immuno electrophoresis and b 2 microglobuline) entered to this study and investigation. all patients received vad regimen (vincristin 0.4mg/day 1-→4 days, adriamycin 9mg/m2 1-→4 days and dexamethasone 40 mg/day/1→4 (days), 9→12 (days), 17→20 (days)/cycle in outpatient therapy (24mg/morning and 16 mg evening) and repeated every 28 days for 4 cycles. the evaluation of response rate was with: decreased clinical manifestation, changes in para clinical profile and m- component and b 2 microglubuline. results: fourty (40) patients enrolled, 24 cases (60%) were female, 16 (40%) male, the mean age was 48 (25- 64), igg myeloma was 80% (32), iga myeloma 15% (6), and igm myeloma 5% (2). 9 cases had thrombocytopenia in initiation of treatment and 7 cases during treatment protocol, and in the end of treatment, thrombocytopenia remained in 3 cases (total 16 cases) with mild thrombocytopenia (plt= 100,000- 120,000), azotemia detected in 7 cases and in 2 cases resolved during treatment protocol. the over all response rate was 85%, median survival to now was 44.3 months. toxicity was mild and acceptable. conclusion: our result revealed the high response rate of vad regimen as initial therapy and good survival rate with minor and acceptable toxicity.
منابع مشابه
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study Group.
BACKGROUND We have previously demonstrated that vincristine, liposomal doxorubicin and dexamethasone (VAD-doxil) is equally effective with VAD-bolus yielding objective response rates of 61% as first-line treatment in multiple myeloma (MM). In a phase II study, the addition of thalidomide to VAD-doxil (TVAD-doxil) proved feasible and increased response rate to 74%. The aim of the present multice...
متن کاملTreatment of Multiple Myeloma
Les traitements classiques de myelome multiple et les schemas differents proposes ont ete mis en revue. La poly chimiotherapie de la maladie avec une com-binaison de cyclophosphamide, B.C.N.U. Alkeran, Perdnisone et Vincristine a donnee une meilleur Resultat ceci surtout dans les formes graves et rapidement progressive de la maladie. D'autres sehemas therapeutiques sont en cours.
متن کاملIV. Initial treatment of multiple myeloma.
The initial treatment of myeloma is rapidly evolving as newer and newer regimens are tested in phase II and III trials [1,2]. Over 20 modern regimens have been reported to be highly effective in a variety of recent trials [3]. Separating ‘promising’ results that should be interpreted as merely hypothesis that need further testing from those that provide clear evidence of clinical benefit requir...
متن کاملMultiple Myeloma Presenting as Respiratory Stridor
Extramedullary plasmacytoma occurs in 18% of patients with multiple myeloma. Laryngeal involvement in multiple myeloma is rare, and only a few cases have been reported. We present a case of a 44-year-old women with multiple myeloma who presented with stridor due to a mass involving the larynx which was initially proven to be plasmacytoma on biopsy. She had evidence of multiple myeloma of IgA la...
متن کاملIs there a role for ‘modified VAD’ in the treatment of multiple myeloma?
VAD, (Vincristine, Doxorubicin and Dexamethasone) was initially proposed as a salvage therapy for myeloma patients in whom prior alkylating agent therapy failed, although in recent years VAD has been surpassed by novel combination therapies with new biological agents such as thalidomide (and its derivative, lenalidomide) and bortezomib. After the excellent results obtained by the novel agents, ...
متن کاملTailoring initial treatment for newly diagnosed, transplantation-eligible multiple myeloma.
High-dose melphalan (Alkeran) and autologous stem cell transplantation are commonly incorporated into the initial line of therapy for patients newly diagnosed with multiple myeloma. This option is usually offered to patients less than 70 years old who have no major comorbidities. Selected older patients and those with mild to moderate organ dysfunction may also be reasonable candidates. An impo...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
international journal of hematology-oncology and stem cell researchجلد ۴، شماره ۴، صفحات ۲۲-۲۴
کلمات کلیدی
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023